PDCD1 and neoplasm: When comparing the efficacy of high-dose romidepsin sequentially or simultaneously with PD1 antibody, high-dose romidepsin significantly inhibited tumour growth compared with PD-1 monotherapy, either in the simultaneous administration group or the sequential administration group.